Passive and active mechanisms trap activated CD8+ T cells in the liver
- PMID: 15100260
- DOI: 10.4049/jimmunol.172.9.5222
Passive and active mechanisms trap activated CD8+ T cells in the liver
Abstract
The liver is a site where activated CD8(+) T cells are trapped and destroyed at the end of an immune response. The intrahepatic accumulation of activated murine TCR transgenic CD8(+) T cells was significantly reduced when either ICAM-1 or VCAM-1 was blocked by specific Ab. These two adhesion mechanisms account for essentially all the trapping of activated CD8(+) T cells in the mouse liver. Although the ICAM-1-mediated trapping depends on the capacity of the vasculature and/or the parenchymal cells to present Ag, the accumulation of cells through VCAM-1 does not require Ag recognition. Thus, Ags expressed by the non-bone marrow-derived cells in the liver actively cause CD8(+) T cell accumulation through TCR-activated ICAM-1 adhesion, but the liver can also passively sequester activated CD8(+) T cells that do not recognize intrahepatic Ag, through VCAM-1 adhesion.
Similar articles
-
Antigen presentation by liver cells controls intrahepatic T cell trapping, whereas bone marrow-derived cells preferentially promote intrahepatic T cell apoptosis.J Immunol. 2001 Jul 15;167(2):667-73. doi: 10.4049/jimmunol.167.2.667. J Immunol. 2001. PMID: 11441069
-
TLR-4 regulates CD8+ T cell trapping in the liver.J Immunol. 2005 Aug 1;175(3):1643-50. doi: 10.4049/jimmunol.175.3.1643. J Immunol. 2005. PMID: 16034104
-
Selective retention of activated CD8+ T cells by the normal liver.J Immunol. 1999 Sep 15;163(6):3202-10. J Immunol. 1999. PMID: 10477588
-
The liver as a site of T-cell apoptosis: graveyard, or killing field?Immunol Rev. 2000 Apr;174:47-62. doi: 10.1034/j.1600-0528.2002.017412.x. Immunol Rev. 2000. PMID: 10807506 Review.
-
Effector CD8 T cell trafficking within the liver.Mol Immunol. 2013 Aug;55(1):94-9. doi: 10.1016/j.molimm.2012.10.032. Epub 2012 Nov 10. Mol Immunol. 2013. PMID: 23149103 Free PMC article. Review.
Cited by
-
The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management.Cancers (Basel). 2024 Feb 15;16(4):795. doi: 10.3390/cancers16040795. Cancers (Basel). 2024. PMID: 38398187 Free PMC article. Review.
-
A computational method for cell type-specific expression quantitative trait loci mapping using bulk RNA-seq data.Nat Commun. 2023 May 25;14(1):3030. doi: 10.1038/s41467-023-38795-w. Nat Commun. 2023. PMID: 37231002 Free PMC article.
-
Fetal liver development and implications for liver disease pathogenesis.Nat Rev Gastroenterol Hepatol. 2023 Sep;20(9):561-581. doi: 10.1038/s41575-023-00775-2. Epub 2023 May 19. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37208503 Review.
-
Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab.Cancer Med. 2023 Apr;12(8):9322-9331. doi: 10.1002/cam4.5689. Epub 2023 Feb 15. Cancer Med. 2023. PMID: 36789624 Free PMC article.
-
Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives.Front Pharmacol. 2023 Jan 9;13:1077468. doi: 10.3389/fphar.2022.1077468. eCollection 2022. Front Pharmacol. 2023. PMID: 36699050 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous